Lentiviral Vector Proprietary Platform

Fully-Optimized Lentiviral Vector Vaccine Platform

MOST EFFICIENT & SAFEST PLATFORM by DESIGN: 20+ years of research and development on lentivirus converge in our vaccine platform, thoroughly optimized to deliver the safest and most efficient lentiviral vector vaccines.

  • Non Replicative
  • Non Pathogenic
  • Optimized Internal Promoter
  • Wide Expression Cassette enabling complex, multi-epitopic immunogen design
  • Enhanced Tropism for Dendritic Cells through VSV pseudotype envelopes
  • No Pre-existing Immunity against vector VSV pseudotypes
  • Sustained endogenous presentation of antigens
  • Prime/Boost and Single Injection Regimen
  • No Adjuvant
  • Low Production Costs due to low active dose
  • Easy Distribution through dry freezing process

SAFETY DEMONSTRATED THROUGH QUANTITATIVE & QUALITATIVE BIODISTRIBUTION STUDIES, CARCINOGENICITY AND ONE PHASE I/IIA STUDY

  • Numerous Clinical Trials using Lentiviral Vectors including CAR-T and Gene Therapy
  • TheraVectys First Product Approved by EMA for Clinical Trial
  • First-in-Human Ph I/IIa performed with no serious adverse event (results to be published)
  • Extensive Toxicology & Animal Studies
  • 25+ Years of Discovery, Development & Knowledge

SPECTACULAR EFFICACY STUDY

An intense, broad & long-lasting T-cell Immune Response

  • Endogenous Antigen Processing leading to sustained Presentation through the whole Dendritic Cell (DC) Life
  • Physiological maturation of DC, no need for adjuvant
  • Long-term T-cell immunity challenged in lethal animal models
Dendritic-cell

Challenged against real pathogens

  • HIV: Best protection ever described in a predictive macaque/SIVmac 251 model
  • Malaria: Unique long-term sterile cellular immunity by a liver-stage vaccine
  • Zika: Long-term sterilizing protection
  • MDR Tuberculosis: unrivaled BCG boost

Back-to-back Comparisons with other vaccine candidates

  • Zika vaccine vs Plasmid & RNA vaccines
  • HIV therapeutic vaccine vs Adeno Boost & VSV vaccines

The vaccine approach with a real chance against Cancer

  • Therapeutic Melanoma Vaccine Challenge shows outstanding results
  • Straight forward approach for virally-induced cancers